NCT06915753 - Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

September 30, 2028

Conditions

Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationAdvanced Solid TumorsFGFR4 Gene MutationFGFR4 Gene FusionsFGF19 Gene AmplificationFGF19 Gene OverexpressionFGFR3 Gene FusionsLocally Advanced Unresectable Hepatocellular Carcinoma

Interventions

DRUG

TYRA-430

Oral TYRA-430 given daily.

Trial Locations (16)

10043

RECRUITING

Columbia University Irving Medical Center, New York

21205

RECRUITING

John Hopkins University, Baltimore

37203

RECRUITING

Sarah Cannon Research Institute Oncology Partners, Nashville

48201

RECRUITING

Karmanos Cancer Institute, Detroit

66205

RECRUITING

The University of Kansas Medical Center, Westwood

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

94158

RECRUITING

UCSF Medical Center at Mount Zion, San Francisco

94305

RECRUITING

Stanford Cancer Institute, Stanford

02114

RECRUITING

Mass General Cancer Center, Boston

M5G 2C4

RECRUITING

University Health Network Princess Margaret Cancer Center, Toronto

Unknown

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Yonsei University Health System, Seoul

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taipei Veterans General Hospital, Taipei

All Listed Sponsors

lead

Tyra Biosciences, Inc

INDUSTRY